Glycolaldehyde dimer

CAS No. 23147-58-2

Glycolaldehyde dimer( 14-Dioxane-25-diol | Hydroxyacetaldehyde dimer | 25-Dihydroxy-14-dioxane )

Catalog No. M19580 CAS No. 23147-58-2

Glycoaldehyde Dimer is derivative of glycolaldehyde which is the precursor molecule of various significant compounds including amino acid glycine and in the formose reaction.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
100MG Get Quote In Stock
200MG 28 In Stock
500MG 37 In Stock
1G 52 In Stock

Biological Information

  • Product Name
    Glycolaldehyde dimer
  • Note
    Research use only, not for human use.
  • Brief Description
    Glycoaldehyde Dimer is derivative of glycolaldehyde which is the precursor molecule of various significant compounds including amino acid glycine and in the formose reaction.
  • Description
    Glycoaldehyde Dimer is derivative of glycolaldehyde which is the precursor molecule of various significant compounds including amino acid glycine and in the formose reaction.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    14-Dioxane-25-diol | Hydroxyacetaldehyde dimer | 25-Dihydroxy-14-dioxane
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    23147-58-2
  • Formula Weight
    120.1
  • Molecular Formula
    C4H8O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    OC1COC(O)CO1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Angiotensin II Recep...

    Angiotensin II Receptor, AT2, Amino Terminal Fragment

  • Pomalidomide-C9-COOH

    Pomalidomide-C9-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

  • CAY10602

    CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening for compounds that increase SIRT1-mediated deacetylation of a SIRT1-specific substrate.